NYSE:PFE

Pfizer Inc (PFE)

24.13
-0.59 (2.39%)
as of Jun 24, 2026, 4:17:43 pm Market Open.
581 watching
0
Investor Insights
star iconJun 24, 2026, 12:00 am

This summary was created by AI, based on 29 opinions in the last 12 months.

Pfizer Inc (PFE) is facing significant challenges as it navigates a patent cliff and the subsequent impacts on revenue after its COVID-19 vaccine boom. Many analysts express concerns about the lack of earnings momentum and the uncertain prospects for new blockbuster drugs in its pipeline. Despite these challenges, PFE maintains an attractive dividend yield ranging from 6% to 7% that provides a steady income for shareholders. The company's strategy includes cost-cutting measures and acquiring smaller companies to refill its drug development pipeline. However, the stock typically trades at a low price-to-earnings ratio, indicating a lack of confidence in future growth, with multiple experts suggesting a need for patience and a potential wait for positive catalysts to drive price appreciation.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
BUY ON WEAKNESS
Good long term track record. Good management. Would like at a lower level.
BUY
Likes the drug sector.
BUY
Sector has been hit hard. At a good level. Prefers Pfizer over Merck.
DON'T BUY
DON'T BUY
Maney that went in as a defensive move is now leaving. Valuation in the sector got too high.
BUY
Excellent company. Should meet their growth potential this year. Great product lines.
WEAK BUY
Company has been doing well. Revenues growing @ 10%, earnings @ 20%. Trading at 19 X. Great long term.
DON'T BUY
Expensive.
TOP PICK
(Was a top pick on Mar 23 no change) A fan of pharmaceuticals and thinks this is the best. Goor R&D and sales.
DON'T BUY
Great com;pany. Valuation is too high.
STRONG BUY
Great product line/sales force. Good price.
DON'T BUY
Has a good pipeline. Should improve towards the end of the year.
DON'T BUY
Great pipeline of products, but has trouble breaking through the $44 level.
DON'T BUY
Very expensive now. 8/10 X Book. Has some potential, but caution.
DON'T BUY
Trading at high multiples.
Showing 811 to 825 of 883 entries